Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/304% below fair value
$29.94−0.54 (-1.76%)
Close on Nov 13, 2026Market cap $1.54BP/E –Yield 0.00%
Immunocore EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Immunocore's EPS for the twelve months ending Sep 30, 2026 was -$0.64. For fiscal 2025 it was -$0.71. The highest annual figure on record is -$0.71 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.71 | – |
| FY2024 | Dec 31, 2024 | -$1.02 | – |
| FY2023 | Dec 31, 2023 | -$1.13 | – |
| FY2022 | Dec 31, 2022 | -$1.15 | – |
| FY2021 | Dec 31, 2021 | -$4.24 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.28 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.02 | – |
| Q1 FY2026 | Mar 31, 2026 | $0.25 | +150.0% |
| Q4 FY2025 | Dec 31, 2025 | -$0.59 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.00 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | -$0.20 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.10 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.47 | – |
| Q3 FY2024 | Sep 30, 2024 | $0.17 | +750.0% |
| Q2 FY2024 | Jun 30, 2024 | -$0.23 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.49 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.40 | – |
| Q3 FY2023 | Sep 30, 2023 | $0.02 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.35 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.40 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?